Abstract Submission Guidelines
Abstract Deadline: **April 1, 2020 @ 11:59PM**, Eastern Daylight Saving Time (EDT)
Abstract Status Notifications: June 2020

Please take a few moments to review the guidelines and sample abstract below.

1. Submission categories and educational objectives
2. Rules for Authors
2. Preparation of Abstracts
3. Sample Abstract
4. Video Submissions

---

1. **Submission Categories and Educational Objectives**

All submissions for moderated sessions will be selected based on SIU Needs Assessment analysis and preference will be given to the following topics which will best serve the educational needs of attendees.

All listed authors must have completed and uploaded a Conflict of Interest Disclosure form (download here).

**Moderated ePoster/Video Topics for Submission (in alpha order)**

- Bladder cancer
- Infections and inflammation
- Kidney cancer
- Lower urinary tract dysfunction
- Penile cancer
- Prostate cancer
- Robotics and minimally invasive surgery
- Reproductive and sexual health
- Stone disease and endourology
- Testis cancer
- Trauma/reconstructive surgery
- Urothelial tumours of the upper urinary tract and ureter

The 2020 Congress Learning Objectives are as follows:

After this educational event, attendees should be able to:

- Determine diagnosis and management of basic and complicated urological infections
• Describe the role of eHealth, new diagnostic methods and delivery of urological education and care in the developing world
• Summarize recent advances in molecular markers for urological diseases
• Report the application of therapeutic modalities and management of complex stone disease
• Discuss multimodal approach to treatment of urological cancers
• List recent advances in minimally invasive surgery
• Describe the current management of lower urinary tract symptoms
• Identify methods of dissemination of knowledge and care to underserved areas

2. Rules for Authors

Prior Publication of Material

The SIU Congress is a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before October 7, 2020. If the work has been presented at another meeting, the author must disclose when and where it was presented (during submission process), so that the Abstract Review Committee can make its decision based on all available details.

Objectivity

The SIU is committed to offering participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the SIU urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.

Registration and Expenses

Abstract status notifications will be sent to all submitters early June. We ask abstract presenters to register before the early-bird registration deadline, which is June 12, 2020; after this date presenting authors who have not paid their registration fees will be excluded from the programme as well as from the SIU Abstract Book and publication on SIU Academy. No exceptions will be granted.

*Abstract presenters who are not SIU members are encouraged to join, as this means a possible savings of at least €200 on registration fees.*

All expenses such as registration, visa, airfare, lodging, etc. associated with the submission and presentation of an abstract are the responsibility of the presenter.

Failure to Present

Should the author (or a designated co-author) of an accepted abstract fail to present the work as scheduled, subsequent abstracts submitted by the individual will be flagged to the scientific committee as coming from a prior "no-show presenter", and will be judged accordingly. This could result in the non-acceptance of future submissions at SIU meetings.

Abstract Acceptance

Each abstract will be blinded and scored by up to three reviewers. Abstracts will be accepted on
the basis of scientific merit.

While abstracts may be submitted as Moderated ePosters, Unmoderated ePosters or Video Posters, the Scientific Committee reserves the right to assign final presentation categories in the best interest of the programme.

Abstract Revisions

Abstracts may not be revised or resubmitted after the deadline of April 1, 2020.

Abstract Withdrawal

Please submit abstract withdrawal requests in writing by June 14, 2020. Please note that if the request is received after this date, it may not be possible to exclude from planned publications.

Change of Presenting Author

Please submit requests in writing by June 12, 2020. After this date, changes will no longer appear in the SIU Abstract Book and SIU Congress materials.

Publication and Copyright

All accepted abstracts will be published in the World Journal of Urology. Publications of abstracts on SIU Academy implies transfer of copyright of the article to the Publisher. This will ensure the widest possible protection and dissemination of information under copyright laws.

SANTU Submissions

Please note that the abstracts that will be considered for SANTU will be only the ones describing surgical techniques, medical management or devices that will be AFFORDABLE in low-income countries. Abstracts submitted to SANTU that do not comply to the "affordability rule" will not be considered. Only authors of submissions selected for SANTU will be contacted by SANTU Organizers.

Please note that while the same abstract may be submitted for both SIU and SANTU, its status with one does not impact the other. SANTU abstracts are not included in the SIU Abstract Book.

2. Preparation of Abstracts

Language

Abstracts must be written and presented in English. Careful typing and proofreading is essential. If accepted, the abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. Once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language in order to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an
immediate revision.

**Word Count**

Abstract should not exceed 350 words. Deduct 50 words for each table or graph included (to a maximum of 1 page).

**Images, Tables and Graphs**

**Images are not permitted**, as they do not reproduce well. Brief and clear tables or graphs are accepted (maximum of 1 page). *If the Tables/Graphs submitted exceed 1 page, those exceeding the limit will be excluded from publication.*

**Topic Area**

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate topic category as indicated on the web submission page.

**Title of Abstract**

Your abstract must have a short, specific title (no abbreviations) that indicates the nature of the investigation. Please use title case.

**Sections**

Abstract **MUST** include the following four distinct sections:
- Introduction and Objective
- Materials and Methods
- Results
- Conclusion

**Drug Names**

Use generic drug names.

**Abbreviations**

Standard abbreviations may be used without definition. Nonstandard abbreviations should be kept to a minimum and placed in parentheses after the first use of the word or phrase.

**Acknowledgments**

Do not include references, credits or grant support.

**Author Names and Affiliations**

**List of authors:** Do NOT include the authors list directly with your abstract. Only submit this information on the online authors form. There is only one presenting author permitted per
submission. All authors must complete, sign and submit a Conflict of Interest disclosure form.

Spelling: If an author's name appears on more than one abstract, it must be identical on each abstract in order to ensure proper indexing.

**Human Experimentation**

Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the investigation should have been conducted in accordance with the principles of the World Medical Association’s Helsinki Declaration. The Scientific Committee may inquire further into ethical aspects when evaluating the abstract(s).

**Abstract Data**

Abstracts that describe single clinical cases, or investigations of compounds that involve inadequate numbers of study subjects, or abstracts that lack quantitative data will not be accepted. Authors should not “split” data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.

Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified.

Statements such as “results will be discussed” will automatically disqualify the abstract. Reviewers require specific data on which to base their evaluation.

*Bear in mind that your abstract will be rated according to the following criteria:*
  • Is the design of the study valid?
  • Are the methods appropriate?
  • What is the significance of the results?
  • Is the event described in the case report significant?

---

3. Sample Abstract

**Complications in Laparoscopic Transperitoneal Partial Nephrectomy**

**Introduction and Objective:** We review the complications of laparoscopic partial nephrectomy in a single surgeon series.

**Materials and Methods:** Between July 1999 and April 2006, a total of 125 patients underwent laparoscopic transperitoneal partial nephrectomy. Mean patient age was 58 years (range 33 to 87) and male to female ratio was 2:1. In 43 patients (34%) the procedure was hand-assisted. A database was kept prospectively for all patients.

**Results:** Mean operative time was 104 minutes (range 35 to 180) and average surgical bleeding was 258 ml (range 0 to 2000). For procedures with warm ischemia, mean arterial clamping time was 26 minutes (range 15 to 60). Mean tumor size was 2.7 cm (range 1 to 7). A total of 14 patients (11.2%) had one or more complications which were intraoperative 6 (4.8%) and postoperative 8 (6.4%) with two delayed complications. Intraoperative hemorrhage occurred in 6 cases (4%), and postoperatively in another 6 (4%). Intraoperative hemorrhage was
managed in 2 cases with laparoscopic radical nephrectomy and in 4 cases with intracorporeal suture. Postoperative hemorrhage required reoperation in 4 patients: two open radical nephrectomies, one laparoscopic radical nephrectomy and one laparoscopic re-suture of the kidney. The remaining two patients were managed with endovascular (percutaneous) embolization. Urine leakage occurred in one case (0.8%) and was managed conservatively with a double-J stent. A digestive hemorrhage and a pulmonary embolism were presented by two patients (1.6%). Transfusion rate was 10.4%. No case required conversion to open surgery. Mean hospital stay was 3.6 days (range 1 to 12).

**Conclusion:** Laparoscopic transperitoneal partial nephrectomy is technically demanding with a high potential for complications. The most frequent complication is either intra- or post-operative hemorrhage. For delayed bleeding, endovascular techniques are safe and effective and thus our first choice in the stable patient.

---

### 4. Video Submissions

**Submission**

If you wish to submit a Video, please use the following link to upload your file: [http://www.siu-urology.org/vimeoapi/](http://www.siu-urology.org/vimeoapi/)

Please note that videos **MUST** be uploaded prior to the submission deadline in order to be considered for review, and also note that a video submission **MUST** include an abstract.

**Format**

All videos must be in the final format and include the exact title, presenting author and production date in submission title. The video itself should be blinded for review. Maximum duration of video: 7 minutes. Submitters may wish to include commentary. All audio and written commentary must be in English.

---

*For any questions pertaining to your abstract submission, please contact: scientific.programme@siu-urology.org.*